A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naive Patients With Low Viral Load.

Trial Profile

A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naive Patients With Low Viral Load.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Hepatitis C DNA vaccine (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Apr 2010 Follow-up results presented in a ChronTech Pharma media release.
    • 28 Apr 2010 Status changed from active, no longer recruiting to completed.
    • 27 Nov 2009 Results have been anounced by Tripep in a media release. Immunological analysis is still underway.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top